ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Dec 18, 2020 13:09 JST
Source:
Eisai
Eisai Completes Construction of the 5th Manufacturing Building at Kawashima Industrial Park in Japan
To Strengthen Its in-House Production Function for Formulating Anti-Cancer Agent Lenvima?
TOKYO, Dec 18, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced that it has completed construction of the 5th manufacturing building at the Kawashima Industrial Park located in Gifu Prefecture, Japan.
External views of the 5th manufacturing building
The 5th manufacturing building is a facility specifically designated for formulating anti-cancer drugs (total floor area: approximately 4,500m2). Since anti-cancer drugs are highly active, this building is designed to make it possible to manufacture anti-cancer agents more safely, with various preventive features for controlling highly active substances, such as preventing cross-contamination of agents and exposure to workers. Eisai plans to manufacture its in-house discovered and developed anti-cancer agent Lenvima, which are in increasing demand worldwide, at this facility from FY2021. We also secure space for further installation of manufacturing equipment for other anti-cancer drugs within this building. The total investment for the construction of the 5th manufacturing building is approximately 5 billion yen.
The Kawashima Industrial Park, opened in 1966, is Eisai?s global pharmaceutical manufacturing base. In addition, this Industrial Park is a role model factory for our global production activities, where we are making new progresses such as utilizing digital technology and new technologies. With the completion of the 5th manufacturing building, Eisai will further expand the stable supply system of high-quality pharmaceuticals in Japan, and continues further contribution to improve the benefits of patients and their families in Japan and around the world.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Hitachi Employee Receives the "Chop Wood Carry Water Award" from the Global OSS Organization CNCF for Leading the Establishment of Official Community in Japan
Nov 14, 2025 21:06 JST
The University of Osaka D3 Center and NEC Demonstrate Wide-Area Distributed Campus AI Processing Platform
Nov 14, 2025 00:41 JST
Toyota to Invest Up to $10 Billion Additional in Its U.S. Operations Over the Next Five Years
Nov 14, 2025 00:08 JST
MHI Thermal Systems Launches Magnetic Bearing Centrifugal Chiller "ETI-N" Series for Japanese Market
Nov 13, 2025 23:34 JST
MHI Completes Joint Demonstration with Kirin Group for Automation of Warehouse Operations, and Truck Loading and Unloading
Nov 13, 2025 23:00 JST
JCB launches second round of Shopping Mall Shuttle Free Ride Campaign in Guam
Nov 13, 2025 11:00 JST
NTT, NTT DOCOMO: Establishment of the AI Technology "Large Action Model (LAM)" to Accelerate 1-to-1 Marketing
Nov 12, 2025 19:00 JST
Mitsubishi Power Receives Second H-25 Gas Turbine Order for Chang Chun Petrochemical's Miaoli Factory in Taiwan
Nov 12, 2025 18:43 JST
All-New Delica Mini and eK Space Win RJC Car of the Year Award for 2026
Nov 12, 2025 18:00 JST
TANAKA PRECIOUS METAL TECHNOLOGIES Announces TK-SR Rhodium Material for Use in Probe Pins
Nov 12, 2025 11:00 JST
Hitachi and Tobu Railway launched a co-creation initiative to deliver HMAX on Japanese railways
Nov 11, 2025 17:35 JST
World Premiere of the New Hilux in Asia
Nov 10, 2025 20:29 JST
MHI Signs EPC Contract for Large-Scale Ammonia and Urea Fertilizer Production Complex for the State Concern Turkmenhimiya
Nov 10, 2025 19:51 JST
Mitsubishi Heavy Industries Announces Order Intake, Revenue, and Profit Growth in Strong 1H FY2025, Raises Full-Year Order Intake and Revenue Guidance
Nov 10, 2025 19:17 JST
MHI Reaches a Basic Agreement with J-POWER on the Transfer of its Domestic Onshore Wind Power Business
Nov 10, 2025 18:40 JST
JFCR and NEC Confirm Research Results for Developing Individualized Neoantigen Cancer Vaccines Using Whole-Genome Data
Nov 10, 2025 18:01 JST
NEC Wheelchair Singles Masters 2025 to begin
Nov 10, 2025 17:32 JST
Indicio Secures Investment from NEC X, Accelerating A New Era of User-Controlled Digital Identity
Nov 10, 2025 17:00 JST
The 18th JCB World Conference Held in Incheon, Republic of Korea
Nov 07, 2025 18:00 JST
Olympus Unveils Corporate Strategy
Nov 07, 2025 15:30 JST
More Latest Release >>
Related Release
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
10/30/2025 2:43:00 PM JST
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
10/29/2025 12:30:00 AM JST
Health Canada Grants Authorization for "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease
10/27/2025 2:23:00 PM JST
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
10/14/2025 5:54:00 PM JST
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
10/8/2025 12:03:00 PM JST
Eisai Highlights Breadth of Oncology Research at ESMO 2025
10/3/2025 6:01:00 PM JST
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
9/29/2025 10:33:00 AM JST
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia
9/24/2025 7:04:00 PM JST
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
9/17/2025 6:20:00 PM JST
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
9/12/2025 1:20:00 PM JST
More Press release >>